Pay in 4 interest-free payments of $6.70 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 Trial
EMA decision anticipated June 2026 Why It Matters: Adherence remains a key barrier in LDL-C management with statins and injectables LEROCHOL introduces meaningful differentiation versus Repatha and Praluent, particularly on storage and usability Expands access to potent lipid lowering for high-risk cardiovascular patients Key Takeaway: LEROCHOL strengthens the PCSK9 landscape with a long-acting, patient-friendly biologicraising the bar on convenience while intensifying competition in cardiovascular risk reduction
Semaglutide is part of a medication class called GLP-1 receptor agonists that targets one hunger hormone
Fasting glucose fell by roughly 911 mg/dL, and HbA1c declined by up to 0.36 percentage points, despite diabetes being an exclusion criterion
Semaglutide is a glucagon-like peptide receptor agonist that sends signals to the brains hypothalamus to regulate blood sugar, metabolize glucose, slow digestion, and make a person feel like theyve had plenty to eat
No more sitting in waiting rooms when you could be relaxing at home
US$ 20.15
US$ 20.79
US$ 21.88
